Cancer Research

Can Nanotechnology Revolutionize Chemotherapy Delivery?
Research & Development Can Nanotechnology Revolutionize Chemotherapy Delivery?

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, particularly in cutting-edge technologies and innovations in the industry. Today, we’re diving into a groundbreaking advancement in cancer treatment—a new formulation of

Can Cabometyx Transform Treatment for Advanced NETs?
Management & Regulatory Can Cabometyx Transform Treatment for Advanced NETs?

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent European Commission approval of Cabometyx for advanced

Protein Drug Delivery Platform – Review
Research & Development Protein Drug Delivery Platform – Review

Imagine a world where life-saving treatments for cancer, autoimmune diseases, and metabolic disorders no longer require hours of intravenous infusions in a clinical setting, allowing patients to administer their medications at home with a quick injection, reclaiming time and autonomy. This scenario

Cancer Neuroscience Unlocks New Immunotherapy Targets
Research & Development Cancer Neuroscience Unlocks New Immunotherapy Targets

In a remarkable stride forward for cancer treatment, researchers have uncovered a profound connection between cancer cells, the nervous system, and immune responses, shedding light on why some patients resist immunotherapy. This emerging field, known as cancer neuroscience, explores how tumors

Review of Modeyso Brain Cancer Treatment
Research & Development Review of Modeyso Brain Cancer Treatment

Imagine a diagnosis so devastating that it offers a median survival of just one year, primarily striking children and young adults with little hope for effective intervention. Diffuse midline glioma with an ### K27M mutation, an ultra-rare and aggressive brain cancer, affects roughly 2,000

Epcoritamab Shines in Phase 3 Trial for Follicular Lymphoma
Research & Development Epcoritamab Shines in Phase 3 Trial for Follicular Lymphoma

What happens when a relentless cancer, deemed incurable, meets a groundbreaking therapy that defies the odds? For the 15,000 Americans diagnosed annually with follicular lymphoma—a slow-growing but persistent form of non-Hodgkin lymphoma—this question is no longer hypothetical. A stunning phase 3

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later